

Meet AZN management: ASCO 2019

Breakout 2: late-stage pipeline

Klaus Edvardsen, Senior Vice President, Oncology R&D, late stage

3 June 2019



Forward-looking statements


In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and price reductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.




Lynparza: ovarian cancer

Leading development programme across lines of treatment


Study 19: overall survival in 'all-comer' 3rd-line+ patients




SOLO3: progression-free survival against CTx¹ in BRCAm 3rd line




SOLO-2: progression-free survival in BRCAm 2nd line



SOLO-1: progression-free survival in BRCAm 1st line



PAOLA-1: 1st-line 'all-comer' ovarian cancer



1. Chemotherapy.
Source: Study 19, abstract 5501, ASCO 2016; and SOLO3, abstract 5506, ASCO 2019.

Source: SOLO-2, 2 - Late Breaking Abstract, SGO 2017; and SOLO-1, European Society of Clinical Oncology meeting 2018.


2. Secondary endpoints.
Source: AstraZeneca data on file.



Lynparza: pancreatic and prostate cancers


Extending benefit of PARP inhibition¹ into new cancer types

POLO: first positive Phase III trial of a PARPi in gBRCAm metastatic pancreatic cancer




Hazard ratio 0.53

PROfound: Phase III in mCRPC² HRRm³ (post abiraterone /enzalutamide)



PROfound data anticipated in H2 2019 - PROpel data anticipated in 2020+

PROpel: Phase III combination of Lynparza and abiraterone in 'all comer' 1L mCRPC



1. Poly (ADP-ribose) polymerase inhibitor.
Source: POLO, abstract LBA4, ASCO 2019.

2. Metastatic castration-resistant prostate cancer.
3. Homologous recombination repair mutation.
Source: AstraZeneca data on file.

Source: AstraZeneca data on file.



Breast cancer: *Lynparza* and *capivasertib*

Going into early disease and new mode of action

OlympiAD: first PARP inhibitor approved in the EU for patients with gBRCAm HER2-negative advanced breast cancer

42%


reduction in the risk of disease progression or death vs. standard of care

52%

objective response rate (ORR) was double that in the chemotherapy arm


OlympiAD approved in EU during H1 2019 - OlympiA Phase III data anticipated in 2020+

OlympiA: gBRCAm adjuvant breast cancer



Source: AstraZeneca data on file.

Capivasertib (AZD5363): novel, oral selective AKT inhibitor
Potential in breast, prostate




Phase III start in Q2 2019

Source: AstraZeneca data on file.



Tagrisso: non-small cell lung cancer

Focus on early-stage disease and resistance



1. Epidermal growth factor receptor mutation 2. Non-small cell lung cancer.
 3. Based on current expectations and event rates, data from the ADAURA trial can be expected in 2022.
 Source: AstraZeneca data on file.

4. Objective response rate.
 Source: AstraZeneca data on file.


Source: AstraZeneca data on file.



Imfinzi: standard of care in unresectable, Stage III NSCLC


Differentially investing to focus on early-stage disease

Unprecedented 11.2 months improvement in median progression-free survival



Proven progression-free survival

>50% of patients receiving Imfinzi were alive at 36 months



Proven overall survival

Early-stage NSCLC trials

Name	Phase	Population	Data
AEGEAN	III	Neo-adjuvant (before surgery)	2020
ADJUVANT.31	III	Stage Ib-IIIa	2020+
PACIFIC-2	III	Unresectable, Stage III NSCLC	2020+
PACIFIC-4	III	Unresectable, Stage III NSCLC	2020+
PACIFIC-5	III	Unresectable, Stage III NSCLC (Asia predominant)	2020+

Source: Antonia, et al., *The New England Journal of Medicine*, 2017.

Source: three-year overall survival update from the PACIFIC trial, abstract 8526, ASCO 2019.

Source: AstraZeneca data on file.



Late-stage Immuno-Oncology strategy

Replace

Create a new treatment paradigm for patients that replaces CTx


Add

Generate additional benefits for patients through additive or combination treatment with CTx

Early

Provide earlier treatment for patients and replace standard of care

Major ongoing late-stage Phase III trials



Source: AstraZeneca Q1 2019 results announcement.



Q&A



Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

